Li Jingqiu, Chong Tsung Wen, Fong Khi Yung, Han Benjamin Lim Jia, Tan Si Ying, Mui Joanne Tan San, Khor Li Yan, Somoni Bhaskar Kumar, Herrmann Thomas R W, Gauhar Vineet, Li Valerie Gan Huei, Sam Christopher Cheng Wai, Lim Ee Jean
Department of Urology, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore.
Ministry of Health Holdings, Singapore, Singapore.
World J Urol. 2025 Apr 1;43(1):200. doi: 10.1007/s00345-025-05583-8.
Urine cytology, while valuable in facilitating the detection and surveillance of bladder cancer, has notable limitations. The application of artificial intelligence (AI) in urine cytology holds significant promise for improving diagnostic accuracy and efficiency. Our scoping review aims to assess the current evidence of AI's utility in urine cytology.
An electronic literature research on the application of AI in the setting of urine cytology was conducted on PubMed, EMBASE, and Scopus from inception to 1st November 2024. Case reports, abstracts, and reviews were excluded from this analysis. Our search strategy retrieved 1356 articles; after excluding 142 duplicates, the remaining 1214 papers were screened by title and abstract. 31 studies entered full-article review, and a total of 16 articles were included in the final analysis.
The main application of AI in urine cytology diagnosis is to automate the identification and characterization of abnormal cells. It has also been utilized for risk stratification of abnormal cells, predicting histologic results from urine cytology samples, and predicting bladder cancer recurrence. Current limitation includes the need for robust training datasets and validation studies to ensure the generalizability of AI algorithms.
In summary, AI in urine cytology, though still developing, shows significant promise in enhancing diagnostic accuracy and efficiency. Current evidence suggests that AI, as a valuable tool, could revolutionize urinary tract cancer diagnosis and management.
尿细胞学检查在促进膀胱癌的检测和监测方面具有重要价值,但也存在显著局限性。人工智能(AI)在尿细胞学检查中的应用有望显著提高诊断准确性和效率。我们的范围综述旨在评估AI在尿细胞学检查中应用的现有证据。
在PubMed、EMBASE和Scopus数据库上进行了一项关于AI在尿细胞学检查中应用的电子文献研究,检索时间从数据库建立至2024年11月1日。本分析排除了病例报告、摘要和综述。我们的检索策略共检索到1356篇文章;排除142篇重复文章后,其余1214篇文章通过标题和摘要进行筛选。31项研究进入全文审查,最终分析共纳入16篇文章。
AI在尿细胞学诊断中的主要应用是实现异常细胞识别和特征描述的自动化。它还被用于异常细胞的风险分层、根据尿细胞学样本预测组织学结果以及预测膀胱癌复发。当前的局限性包括需要强大的训练数据集和验证研究,以确保AI算法的通用性。
总之,尿细胞学检查中的AI虽然仍在发展,但在提高诊断准确性和效率方面显示出巨大潜力。现有证据表明,AI作为一种有价值的工具,可能会彻底改变尿路癌的诊断和管理。